About MEPs Against Cancer

The MAC Group was founded in 2005 and remains the only dedicated group to cancer policy at the European Parliament. Currently there are 36 MAC members coming from all political groups and different EU Member States. The President Mr. Alojz Peterle (EPP, Slovenia), Vice-Presidents Ms. Nessa Childers (S&D, Ireland), Mr. Pavel Poc (S&D, Czech Republic), and Dr. Charles Tannock (ECR, United Kingdom), and other members are committed to taking action in the fight against cancer. The MEPs Against Cancer (MAC) work together in order to improve cancer control and prevention in Europe, in the belief that European cooperation adds value to member state actions. In order to address the challenges faced by the EU, MAC collaborate with the European Commission, the Council and other relevant organisations to reduce cancer incidence by 15% by 2020.

STRATEGIC GOALS 2014-2019

I. Reducing cancer incidence by promoting prevention
II. Reducing mortality by ensuring equitable access to high quality treatment and care
III. Ensuring a good quality of life for cancer patients and survivors

 

 

Quote from the President 

“I think it is crucial for this term to provide more added value in the fight against cancer at the EU level, as well as better co-operation with stakeholders in the Member States. What is of the utmost importance is a concrete preventive policy in order to diminish the inflow of new cancer patients, which has been also the wish of the cancer patients in the EU.”

Alojz Peterle,
MAC President

SECRETARIAT

The MEPs Against Cancer group receives secretarial support from the Association of European Cancer Leagues (ECL), a Brussels‐based non‐profit organisation who represents national cancer societies across Europe. If you would like to become a member of MAC and make a difference in cancer control, receive more information about our initiatives or organise and event with MAC MEPs, please visit www.mepsagainstcancer.eu or contact us at MAC(at)europeancancerleagues.org.

Download MAC Leaflet
MAC Strategic Roadmap 2014-19